Literature DB >> 2009918

Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo.

V Ley1, P Langlade-Demoyen, P Kourilsky, E L Larsson-Sciard.   

Abstract

We have quantitatively studied the effect of interleukin (IL) 2 on the cytotoxic T lymphocyte (CTL) response to tumor cells in vivo. Mastocytoma P815 was transfected with murine IL 2 cDNA (P815-IL 2) and injected into syngeneic mice. The anti-tumor response was analyzed and compared with the response induced by the non-transfected cells. P815 parental cells are highly tumorigenic, causing death within 20-30 days. In contrast, IL 2-transfected cells were totally rejected. Co-injection of IL 2-secreting and parental cells resulted in the inhibition of growth of both type of tumors. In addition, the response induced by IL 2-secreting cells protected the mice against a subsequent challenge with P815. Long-term memory persisted in treated mice 3 months after tumor rejection. Frequencies of CTL precursors and CTL specific for P815 increased as a result of IL 2 secretion by the target cells. Estimates of CTL frequency at days 8 and 12 after injection were 2 to 3 times higher in mice inoculated with P815-IL 2 cells, and this correlated with tumor rejection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2009918     DOI: 10.1002/eji.1830210350

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  19 in total

1.  Prevention of hepatic tumor metastases in rats with herpes viral vaccines and gamma-interferon.

Authors:  H M Karpoff; M D'Angelica; S Blair; M D Brownlee; H Federoff; Y Fong
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

Review 2.  Cancer gene and immunotherapy: recent developments.

Authors:  P Jantscheff; R Herrmann; C Rochlitz
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

3.  Herpes simplex virus (HSV)-mediated ICAM-1 gene transfer abrogates tumorigenicity and induces anti-tumor immunity.

Authors:  M D'Angelica; C Tung; P Allen; M Halterman; K Delman; T Delohery; D Klimstra; M Brownlee; H Federoff; Y Fong
Journal:  Mol Med       Date:  1999-09       Impact factor: 6.354

4.  Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.

Authors:  J H Sampson; G E Archer; D M Ashley; H E Fuchs; L P Hale; G Dranoff; D D Bigner
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

5.  Cancer vaccines: the interleukin 2 dosage effect.

Authors:  W Schmidt; T Schweighoffer; E Herbst; G Maass; M Berger; F Schilcher; G Schaffner; M L Birnstiel
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

Review 6.  IL-2 gene therapy of solid tumors: an approach for the prevention of signal transduction defects in T cells.

Authors:  K S Zier; B Gansbacher
Journal:  J Mol Med (Berl)       Date:  1996-03       Impact factor: 4.599

7.  Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice.

Authors:  Jennifer A Westwood; Phillip K Darcy; Preethi Mayura Guru; Janelle Sharkey; Hollie J Pegram; Sally M Amos; Mark J Smyth; Michael H Kershaw
Journal:  J Transl Med       Date:  2010-04-28       Impact factor: 5.531

Review 8.  Interleukin-2 in cancer treatment: disappointing or (still) promising? A review.

Authors:  R A Maas; H F Dullens; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

Review 9.  Strategies for cytokine utilisation in tumor therapy.

Authors:  F Di Pierro; F Cavallo; F Pericle; S Bertini; M Giovarelli; G Forni
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

10.  Preservation of mucosal and systemic adjuvant properties of ISCOMS in the absence of functional interleukin-4 or interferon-gamma.

Authors:  R E Smith; A M Donachie; F H McLaren; A M Mowat
Journal:  Immunology       Date:  1998-04       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.